Pancreatic Adverse Events Associated With Immune Checkpoint Inhibitors: A Large-Scale Pharmacovigilance Analysis

Backgrounds: Immune checkpoint inhibitors (ICIs) are considered cornerstones of oncology treatment with durable anti-tumor efficacy, but the increasing use of ICIs is associated with the risk of developing immune-related adverse events (irAEs). Although ICI-associated pancreatic adverse events (AEs)...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Yue Zhang, Yisheng Fang, Jianhua Wu, Genjie Huang, Jianping Bin, Yulin Liao, Min Shi, Wangjun Liao, Na Huang
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Frontiers Media S.A. 2022-04-01
Serie:	Frontiers in Pharmacology
Soggetti:	immune checkpoint inhibitors PD-1/PD-L1 CTLA-4 combination therapy pancreatic adverse events pancreatitis
Accesso online:	https://www.frontiersin.org/articles/10.3389/fphar.2022.817662/full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!